The study and its comparison
A randomized trial included 644 participants. The study population was infertile women with polycystic ovary syndrome. Researchers compared berberine 1.5 g daily, letrozole, or their combination, with follow-up over up to six months. [1]
Cumulative live births were 36% with letrozole, 34% with the combination and 22% with berberine alone. Adding berberine did not improve live birth, and berberine alone performed worse than the letrozole-containing regimens. [1]
What the finding establishes
A mechanism involving insulin or reproductive hormones cannot replace the measured fertility outcome. The research concerns supervised infertility treatment, not supplement use during an established pregnancy. It also cannot establish a general estrogen-lowering effect or show that berberine substitutes for ovulation-induction medication. Funding and complete conflicts were not established from the retrieved abstract. [1]
A hypothetical distinction
Imagine a combination changes a proposed mechanism but does not increase live births. The mechanism is not an added clinical benefit.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Randomized controlled trial of letrozole, berberine, or a combination for infertility in the polycystic ovary syndrome.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.